AstraZeneca sell-off tests investor confidence in drug pipeline
A late-stage Wainua trial failure erased more from AstraZeneca’s shares than analysts’ valuation models suggested, putting focus on upcoming drug readouts.
By Marcus V. Thorne · Markets Editor
· 3 min read
AstraZeneca shares fell 6.2% on Thursday after a late-stage trial of Wainua failed in ATTR cardiomyopathy, the stock’s steepest one-day decline in more than two years. Analysts cited by CNBC estimated the missed trial cut only about 2% to 4% from valuation models, indicating that investors were also reassessing the premium attached to the company’s broader drug pipeline.
The setback concerned Wainua as a potential treatment for ATTR cardiomyopathy, a rare and life-threatening heart condition. The drug was not widely expected to become one of AstraZeneca’s largest products, but analysts said the trial had been viewed as relatively likely to succeed, partly because Alnylam’s rival medicine Amvuttra had produced favorable precedent and works in a similar way.
AstraZeneca’s London-listed shares declined a further 3% on Friday, according to CNBC. A company spokesperson declined to comment further on the share-price reaction.
Valuation impact appears limited
Several brokerage estimates put the direct financial effect below the market move. Citi calculated the net present value impact at roughly 3%, Jefferies estimated about 2%, and Leerink Partners’ target-price reduction implied a similarly contained hit. Bank of America described the expected sales impact as mid-single digit, while Morningstar said lower Wainua sales estimates did not materially alter its valuation.
Net present value models discount expected future product sales back to today, adjusted for costs, timing and development risk. A single trial failure can therefore reduce a company’s estimated worth, but the share-price impact may be larger if investors also lower the probability they assign to other drugs reaching the market.
That broader reassessment is now central to the debate around AstraZeneca. Under Chief Executive Pascal Soriot, who has led the company for 14 years, the group has built a reputation for strong late-stage clinical execution across oncology, rare diseases and specialty medicines. That record has supported one of the richer valuations among large European pharmaceutical companies.
Jefferies analysts wrote on Thursday that the issue extended beyond the incremental revenue Wainua might have contributed, saying the failed study affected the company’s credibility. The analysts said the trial had been expected to be a “slam dunk,” which made the outright failure surprising.
2030 sales target remains in focus
Dan Coatsworth, head of markets at AJ Bell, said in emailed comments that AstraZeneca’s recent record of more successes than failures had raised investor expectations. He said investors would now question the credibility of management’s plan to reach $80 billion in sales by 2030.
Analysts largely said the failure did not invalidate that longer-term target. Jefferies said the trial result did not threaten management’s 2030 ambition, while Citi said it still expected AstraZeneca to exceed the goal. Leerink said that, after speaking with management, removing Wainua in ATTR cardiomyopathy reduced the buffer above company-provided consensus from about $82.7 billion to about $80.8 billion, reflecting $1.9 billion of expected Wainua revenue in 2030.
Morningstar left its fair value estimate unchanged, saying the result did not change its view of AstraZeneca’s late-stage development capabilities. It also said the company’s oncology franchise, rare disease business and wider pipeline remained intact.
Upcoming readouts carry more weight
The failed Wainua study arrives before several significant AstraZeneca data releases. Analysts cited AVANZAR in lung cancer, SERENA-4 in breast cancer and cliramitug in ATTR cardiomyopathy as expected readouts over the coming months.
Jefferies described AVANZAR, expected in July or August, as the next major catalyst likely to influence investor sentiment. Leerink said the setback placed more emphasis on the remaining binary events due later in the year.
Citi maintained AstraZeneca as its top European pharmaceutical pick, Bank of America reiterated its Buy rating, and Jefferies retained a positive view of the shares, according to CNBC. Those ratings are analysts’ opinions and do not remove the execution risk now attached to the company’s next clinical milestones.
This story draws on original reporting from CNBC.
